Kopp Investment Advisors LLC Sells 1,000 Shares of Vericel Corporation (VCEL)
Kopp Investment Advisors LLC decreased its position in Vericel Corporation (NASDAQ:VCEL) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,040 shares of the biotechnology company’s stock after selling 1,000 shares during the period. Kopp Investment Advisors LLC owned 0.16% of Vericel Corporation worth $178,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Vericel Corporation by 13.8% in the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 4,523 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in Vericel Corporation by 12.6% in the second quarter. Perkins Capital Management Inc. now owns 257,600 shares of the biotechnology company’s stock valued at $850,000 after acquiring an additional 28,850 shares during the last quarter. First Washington CORP bought a new position in Vericel Corporation in the second quarter valued at about $2,230,000. Vanguard Group Inc. boosted its holdings in Vericel Corporation by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after acquiring an additional 88,645 shares during the last quarter. Finally, Archon Capital Management LLC bought a new position in Vericel Corporation in the second quarter valued at about $4,412,000. Institutional investors and hedge funds own 33.84% of the company’s stock.
Vericel Corporation (NASDAQ VCEL) traded up 0.455% during trading on Thursday, reaching $5.525. The company’s stock had a trading volume of 392,761 shares. The firm has a 50 day moving average price of $3.81 and a 200-day moving average price of $3.11. The stock’s market cap is $181.35 million. Vericel Corporation has a 52-week low of $2.00 and a 52-week high of $5.80.
Vericel Corporation (NASDAQ:VCEL) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.16. The business had revenue of $16.95 million for the quarter. On average, analysts expect that Vericel Corporation will post ($0.63) earnings per share for the current year.
Several equities analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $6.00 price target on shares of Vericel Corporation in a report on Thursday, September 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $7.00 target price on shares of Vericel Corporation in a research note on Thursday, August 10th.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/28/kopp-investment-advisors-llc-sells-1000-shares-of-vericel-corporation-vcel.html.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL).
Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.